GlassScriptPhysician profile
Sandra Lee Aaron
NPI 1801561964
$2,320.80
in general payments reported to CMS, 2019-2025
27 companies · $611 in 2025
The $611 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $239 · 2023: $665 · 2024: $805 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390.26 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $388.35 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $229.93 | 2022-2025 | Shingrix, Arexvy, Boostrix |
| Lilly USA, LLC | $167.76 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $112.03 | 2022-2024 | Freestyle Libre 3, Eterna |
| Astrazeneca Pharmaceuticals LP | $109.87 | 2022-2024 | Farxiga |
| Astellas Pharma US INC | $101.67 | 2023-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $98.75 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Boston Scientific Corporation | $94.20 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Dexcom, INC. | $66.52 | 2022-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $58.88 | 2024-2025 | Mazor X System, Intellis Adaptivestim, Venaseal |
| Shield Therapeutics INC | $53.70 | 2024-2025 | |
| Exact Sciences Corporation | $49.99 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $45.62 | 2023 | |
| Sumitomo Pharma America, INC. | $40.13 | 2025 | Gemtesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $39.59 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.34 | 2022-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.28 | 2024-2025 | Xifaxan, Trulance |
| Inspire Medical Systems, INC. | $33.65 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $31.28 | 2023 | Steglatro, Belsomra |
| Globus Medical, INC. | $29.67 | 2025 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.01 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $17.60 | 2025 | |
| Pfizer INC. | $17.56 | 2023 | |
| Amgen INC. | $16.40 | 2022 | |
| Lundbeck LLC | $16.29 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $13.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Aaron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.